OR WAIT null SECS
Xiamen Origin Biotech Co., Ltd, was cited, not only for inadequate quality management, but for falsifying information on certificates of analysis, having fictional employees sign CoAs, and having employees lie to inspectors.
In a warning letter sent to Mr. Zhang Jian, owner of Xiamen Origin on July 19, and published on FDA’s web site on August 2, 2016, the Agency has charged with company with a number of compliance and data integrity failures.
The following were singled out in the letter from Francis Godwin, Acting Director of CDER’s Office of Manufacturing Quality:
FDA inspectors allege that the firm had no written procedures for qualifying suppliers, relabeling, sampling, product release, document retention or training.
The company “repeatedly falsified and omitted information on the certificates of analysis given to customers. In one case, FDA inspectors say, the company made up an employee and used his name and signature on the CoA. In addition, the company left out the name and address of the original API manufacturer and did not include a copy of the original batch certificate. An expiration date on a CoA exceeded the manufacturer’s labeled expiration date.
One employee told the investigator that there were no drugs on site, and that the company had stopped relabeling drugs in 2015. The inspector found an exported drugs list that showed that the company had distributed drugs from January 2015 to January 2016.